← All trials
NCT05533008
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2019
- Primary completion
- Jun 11, 2020
- Completion date
- Jun 11, 2020
- First posted
- Sep 8, 2022
- Last posted
- Sep 8, 2022
- Enrollment
- 35
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cara TherapeuticsLead sponsor
- Cara TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.